Viva Biotech launches $194m HK flotation
Viva Biotech Holdings has kicked off bookbuilding for its Hong Kong listing, eyeing proceeds of up to HK$1.52bn ($194m). The firm has secured the support of Chinese state-owned giant Sinopharm.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: